Fujian Wanchen Biotechnology Co. Ltd (300972) — Capital Reinvestment Ratio

Latest as of December 2025: 0.02x

Fujian Wanchen Biotechnology Co. Ltd (300972) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥3.63 Billion) in capital expenditures (CN¥77.44 Million). Check tangible net worth ratio of Fujian Wanchen Biotechnology Co. Ltd to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥3.63 Billion
CNY

Capital Expenditures

CN¥77.44 Million
CNY

Data as of

Dec 2025
Most recent filing

Fujian Wanchen Biotechnology Co. Ltd Capital Reinvestment Ratio (2019–2025)

This chart tracks Fujian Wanchen Biotechnology Co. Ltd's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Fujian Wanchen Biotechnology Co. Ltd.

Annual Capital Reinvestment Ratio for Fujian Wanchen Biotechnology Co. Ltd (2019–2025)

Year-by-year Capital Reinvestment Ratio for Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2025. See 300972 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.02x CN¥3.63 Billion CN¥77.44 Million ▼ -84.5%
2024 0.14x CN¥848.35 Million CN¥116.65 Million ▼ -35.7%
2023 0.21x CN¥1.02 Billion CN¥218.91 Million ▼ -95.2%
2022 4.49x CN¥70.38 Million CN¥316.34 Million ▲ +968.4%
2021 0.42x CN¥98.82 Million CN¥41.57 Million ▲ +17.2%
2020 0.36x CN¥156.24 Million CN¥56.10 Million ▲ +60.2%
2019 0.22x CN¥177.28 Million CN¥39.73 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow